|
1
|
De Coster S, van Leeuwen DM, Jennen DG,
Koppen G, Den Hond E, Nelen V, Schoeters G, Baeyens W, van Delft
JH, Kleinjans JC and van Larebeke P: Gender-specific transcriptomic
response to environmental exposure in Flemish adults. Environ Mol
Mutagen. 54:574–588. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bergan HE, Kittilson JD and Sheridan MA:
PKC and ERK mediate GH-stimulated lipolysis. J Mol Endocrinol.
51:213–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nair HB, Perla RP, Kirma NB, Krishnegowda
NK, Ganapathy M, Rajhans R, Nair SS, Saikumar P, Vadlamudi RK and
Tekmal RR: Estrogen receptor-beta mediates the protective effects
of aromatase induction in the MMTV-Her-2/neu × aromatase double
transgenic mice. Horm Cancer. 3:26–36. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ali S and Coombes RC: Estrogen receptor
alpha in human breast cancer: Occurrence and significance. J
Mammary Gland Biol Neoplasia. 5:271–281. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Omoto Y, Inoue S, Ogawa S, Toyama T,
Yamashita H, Muramatsu M, Kobayashi S and Iwase H: Clinical value
of the wild-type estrogen receptor beta expression in breast
cancer. Cancer Lett. 163:207–212. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roger P, Sahla ME, Mäkelä S, Gustafsson
JA, Baldet P and Rochefort H: Decreased expression of estrogen
receptor beta protein in proliferative preinvasive mammary tumors.
Cancer Res. 61:2537–2541. 2001.PubMed/NCBI
|
|
7
|
Hayashi SI, Eguchi H, Tanimoto K, Yoshida
T, Omoto Y, Inoue A, Yoshida N and Yamaguchi Y: The expression and
function of estrogen receptor alpha and beta in human breast cancer
and its clinical application. Endocr Relat Cancer. 10:193–202.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fox EM, Davis RJ and Shupnik MA: ERbeta in
breast cancer - onlooker, passive player, or active protector?
Steroids. 73:1039–1051. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Edge SB, Byrd DR, Compton CC, et al:
Breast. AJCC cancer staging manual (7th). (New York, NY). Springer.
347–376. 2010.
|
|
10
|
Osborne CK and Schiff R: Mechanisms of
endocrine resistance in breast cancer. Annu Rev Med. 62:233–247.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mestron A, Webb SM, Astorga R, et al:
Epidemiology, clinical characteristics, outcome, morbidity and
mortality in acromegaly based on the Spanish Acromegaly Registry
(Registro Espanol de Acromegalia, REA). Eur J Endocrinol.
151:439–446. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li SL and Chen XPWK: The biological
characteristics and clinical treatments of breast cancer. Sl L:
Beijing: Science Press. 2004.
|
|
13
|
Hammond ME, Hayes DF, Wolff AC, Mangu PB
and Temin S: American society of clinical oncology/college of
american pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Oncol Pract. 6:195–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guideline Recommendations for HER2
Detection in Breast Cancer Group: Guidelines for HER2 detection in
breast cancer, the 2009 version. Zhonghua Bing Li Xue Za Zhi.
38:836–840. 2009.(In Chinese). PubMed/NCBI
|
|
15
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chaves VE, Júnior FM and Bertolini GL: The
metabolic effects of growth hormone in adipose tissue. Endocrine.
44:293–302. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang HG, Kim SJ, Chung KW, Noh DY, Kwon
Y, Lee ES and Kang HS: Tamoxifen-resistant breast cancers show less
frequent methylation of the estrogen receptor beta but not the
estrogen receptor alpha gene. J Mol Med (Berl). 83:132–139. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Esslimani-Sahla M, Simony-Lafontaine J,
Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA and
Rochefort H: Estrogen receptor beta (ER beta) level but not its ER
beta cx variant helps to predict tamoxifen resistance in breast
cancer. Clin Cancer Res. 10:5769–5776. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chung YL, Sheu ML, Yang SC, Lin CH and Yen
SH: Resistance to tamoxifen-induced apoptosis is associated with
direct interaction between Her2/neu and cell membrane estrogen
receptor in breast cancer. Int J Cancer. 97:306–312. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mosselman S, Polman J and Dijkema R: ER
beta: Identification and characterization of a novel human estrogen
receptor. FEBS Lett. 392:49–53. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park BW, Kim KS, Heo MK, Ko SS, Hong SW,
Yang WI, Kim JH, Kim GE and Lee KS: Expression of estrogen
receptor-beta in normal mammary and tumor tissues: Is it protective
in breast carcinogenesis? Breast Cancer Res Treat. 80:79–85. 2003.
View Article : Google Scholar : PubMed/NCBI
|
